These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
264 related articles for article (PubMed ID: 37217796)
21. Ceftazidime-avibactam, meropenen-vaborbactam, and imipenem-relebactam in combination with aztreonam against multidrug-resistant, metallo-β-lactamase-producing Klebsiella pneumoniae. Maraki S; Mavromanolaki VE; Moraitis P; Stafylaki D; Kasimati A; Magkafouraki E; Scoulica E Eur J Clin Microbiol Infect Dis; 2021 Aug; 40(8):1755-1759. PubMed ID: 33595756 [TBL] [Abstract][Full Text] [Related]
22. Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli. Scudeller L; Righi E; Chiamenti M; Bragantini D; Menchinelli G; Cattaneo P; Giske CG; Lodise T; Sanguinetti M; Piddock LJV; Franceschi F; Ellis S; Carrara E; Savoldi A; Tacconelli E Int J Antimicrob Agents; 2021 May; 57(5):106344. PubMed ID: 33857539 [TBL] [Abstract][Full Text] [Related]
23. Assessing the in vivo impact of novel β-lactamase inhibitors on the efficacy of their partner β-lactams against serine carbapenemase-producing Pseudomonas aeruginosa using human-simulated exposures. Ruiz VH; Gill CM; Nicolau DP J Antimicrob Chemother; 2024 Mar; 79(3):546-551. PubMed ID: 38217443 [TBL] [Abstract][Full Text] [Related]
24. Efficacy of ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam combinations against carbapenemase-producing Enterobacterales in Switzerland. Nordmann P; Bouvier M; Poirel L Eur J Clin Microbiol Infect Dis; 2023 Sep; 42(9):1145-1152. PubMed ID: 37566365 [TBL] [Abstract][Full Text] [Related]
25. In vitro activities of ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam and other comparators against Pseudomonas aeruginosa isolates with discrepant resistance to carbapenems: Data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2012-2021. Lee YL; Ko WC; Hsueh PR Int J Antimicrob Agents; 2023 Aug; 62(2):106867. PubMed ID: 37244423 [TBL] [Abstract][Full Text] [Related]
26. Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae. Haidar G; Clancy CJ; Chen L; Samanta P; Shields RK; Kreiswirth BN; Nguyen MH Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630202 [TBL] [Abstract][Full Text] [Related]
27. Activity of cefiderocol and synergy of novel β-lactam-β-lactamase inhibitor-based combinations against metallo-β-lactamase-producing gram-negative bacilli: insights from a two-year study (2019-2020). Boattini M; Comini S; Bianco G; Iannaccone M; Casale R; Cavallo R; Costa C J Chemother; 2023 May; 35(3):198-204. PubMed ID: 35731718 [TBL] [Abstract][Full Text] [Related]
28. A Systematic Review of the Pharmacokinetics and Pharmacodynamics of Novel Beta-Lactams and Beta-Lactam with Beta-Lactamase Inhibitor Combinations for the Treatment of Pneumonia Caused by Carbapenem-Resistant Gram-Negative Bacteria. Rando E; Novy E; Sangiorgi F; De Pascale G; Fantoni M; Murri R; Roberts JA; Cotta MO Int J Antimicrob Agents; 2024 Sep; 64(3):107266. PubMed ID: 38971203 [TBL] [Abstract][Full Text] [Related]
29. In vitro activities of ceftazidime/avibactam alone or in combination with antibiotics against multidrug-resistant Acinetobacter baumannii isolates. Mataracı Kara E; Yılmaz M; Özbek Çelik B J Glob Antimicrob Resist; 2019 Jun; 17():137-141. PubMed ID: 30576787 [TBL] [Abstract][Full Text] [Related]
31. New options for bloodstream infections caused by colistin- or ceftazidime/avibactam-resistant Klebsiella pneumoniae. Yu W; Luo Q; Shen P; Chen Y; Xu H; Xiao Y; Qiu Y Int J Antimicrob Agents; 2021 Dec; 58(6):106458. PubMed ID: 34706255 [TBL] [Abstract][Full Text] [Related]
32. Evaluation of the inoculum effect of new antibiotics against carbapenem-resistant enterobacterales. Danjean M; Hobson CA; Gits-Muselli M; Courroux C; Monjault A; Bonacorsi S; Birgy A Clin Microbiol Infect; 2022 Nov; 28(11):1503.e1-1503.e3. PubMed ID: 35777602 [TBL] [Abstract][Full Text] [Related]
33. Synergism of eravacycline combined with other antimicrobial agents against carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii. Li Y; Cui L; Xue F; Wang Q; Zheng B J Glob Antimicrob Resist; 2022 Sep; 30():56-59. PubMed ID: 35660472 [TBL] [Abstract][Full Text] [Related]
34. Effect of modification of penicillin-binding protein 3 on susceptibility to ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam, aztreonam-avibactam, cefepime-taniborbactam, and cefiderocol of Le Terrier C; Nordmann P; Buchs C; Poirel L Antimicrob Agents Chemother; 2024 Apr; 68(4):e0154823. PubMed ID: 38415988 [TBL] [Abstract][Full Text] [Related]
35. Epidemiology and in vitro activity of ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam, eravacycline, plazomicin, and comparators against Greek carbapenemase-producing Klebsiella pneumoniae isolates. Maraki S; Mavromanolaki VE; Magkafouraki E; Moraitis P; Stafylaki D; Kasimati A; Scoulica E Infection; 2022 Apr; 50(2):467-474. PubMed ID: 34854060 [TBL] [Abstract][Full Text] [Related]
36. [In vitro synergistic activity of sulbactam in combination with imipenem, meropenem and cefoperazone against carbapenem-resistant Acinetobacter baumannii isolates]. Turk Dagi H; Kus H; Arslan U; Tuncer I Mikrobiyol Bul; 2014 Apr; 48(2):311-5. PubMed ID: 24819268 [TBL] [Abstract][Full Text] [Related]
38. Simultaneous and divergent evolution of resistance to cephalosporin/β-lactamase inhibitor combinations and imipenem/relebactam following ceftazidime/avibactam treatment of MDR Pseudomonas aeruginosa infections. Alonso-García I; Vázquez-Ucha JC; Lasarte-Monterrubio C; González-Mayo E; Lada-Salvador P; Vela-Fernández R; Aja-Macaya P; Guijarro-Sánchez P; Rumbo-Feal S; Muíño-Andrade M; Fernández-González A; Martínez-Guitián M; Beceiro A; Rodríguez-Iglesias M; Oliver A; Arca-Suárez J; Galán-Sánchez F; Bou G J Antimicrob Chemother; 2023 May; 78(5):1195-1200. PubMed ID: 36918743 [TBL] [Abstract][Full Text] [Related]
39. Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Ackley R; Roshdy D; Meredith J; Minor S; Anderson WE; Capraro GA; Polk C Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32094128 [TBL] [Abstract][Full Text] [Related]
40. In vitro activity of imipenem/relebactam, meropenem/vaborbactam and comparators against Enterobacterales causing urinary tract infection in Taiwan: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2020. Chang CY; Lee YL; Huang YT; Ko WC; Ho MW; Hsueh PR Int J Antimicrob Agents; 2023 Jun; 61(6):106815. PubMed ID: 37059343 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]